Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation
Journal of the American College of Cardiology, Volume 79, No. 8, Year 2022
Notification
URL copied to clipboard!
Description
Background: The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain. Objectives: The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB). Methods: Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE. The study used data from the Infectious Endocarditis after TAVI International Registry. Results: Among 584 patients, 111 patients (19%) were treated with IE-CS and 473 patients (81%) with IE-AB. Compared with IE-AB, IE-CS was not associated with a lower in-hospital mortality (HRunadj: 0.85; 95% CI: 0.58-1.25) and 1-year all-cause mortality (HRunadj: 0.88; 95% CI: 0.64-1.22) in the crude cohort. After adjusting for selection and immortal time bias, IE-CS compared with IE-AB was also not associated with lower mortality rates for in-hospital mortality (HRadj: 0.92; 95% CI: 0.80-1.05) and 1-year all-cause mortality (HRadj: 0.95; 95% CI: 0.84-1.07). Results remained similar when patients with and without TAVI prosthesis involvement were analyzed separately. Predictors for in-hospital and 1-year all-cause mortality included logistic EuroSCORE I, Staphylococcus aureus, acute renal failure, persistent bacteremia, and septic shock. Conclusions: In this registry, the majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery was not associated with an improved all-cause in-hospital or 1-year mortality. The high mortality of patients with TAVI-IE was strongly linked to patients’ characteristics, pathogen, and IE-related complications. © 2022 American College of Cardiology Foundation
Authors & Co-Authors
Abdel-Wahab, Mohamed Kader
Germany, Leipzig
Herzzentrum Leipzig
Durand, Éric
France, Caen
Normandie Université
Ihlemann, Nikolaj
Denmark, Copenhagen
Rigshospitalet
Pellegrini, Costanza
Germany, Munich
Technische Universität München
Giannini, F.
Italy, Milan
Irccs Ospedale San Raffaele
Wojakowski, Wojciech
Poland, Katowice
Slaski Uniwersytet Medyczny w Katowicach
Landt, Martin
Unknown Affiliation
Sinning, Jan Malte
Unknown Affiliation
Cheema, Asim N.
Canada, Toronto
Saint Michael's Hospital University of Toronto
Nombela-Franco, Luís
Spain, Madrid
Hospital Clínico San Carlos
Campelo-Parada, Francisco
France, Toulouse
Hôpital Rangueil
Testa, Luca
Italy, San Donato Milanese
Gruppo Ospedaliero San Donato
Kim, Won-keun
Unknown Affiliation
Tchétché, Didier
France, Toulouse
Clinique Pasteur
Bartorelli, Antonio L.
Italy, Milan
Università Degli Studi Di Milano
Kapadia, Samir R.
United States, Cleveland
Cleveland Clinic Foundation
Stortecky, Stefan
Switzerland, Bern
University of Bern
Amat, Ignacio J.
Spain, Madrid
Centro de Investigación en Red en Enfermedades Cardiovasculares
Wijeysundera, Harindra Channa
Canada, Toronto
Sunnybrook Health Sciences Centre
Livi, Ugolino
Italy, Udine
Policlinico Universitario, Udine
Lerakis, Stamatios
United States, Atlanta
Emory University School of Medicine
United States, New York
The Mount Sinai Hospital
Kappert, Utz W.
Germany, Dresden
Herzzentrum Dresden Universitätsklinik
Barbanti, Marco
Italy, Catania
Azienda Ospedaliero Universitaria Policlinico G.rodolico - San Marco
Fiorina, Claudia
Italy, Brescia
Spedali Civili Di Brescia
Miceli, Antonio
Italy, Milan
Istituto Clinico Sant’ambrogio
Ireland, Galway
University Hospital Galway
Kodali, Susheel K.
United States, New York
Columbia University Irving Medical Center
Ribeiro, Henrique B.
Brazil, Sao Paulo
Universidade de São Paulo
Brazil, Sao Paulo
Hospital Samaritano
Mangione, José Armando
Brazil, Paraiso
Beneficenca Portuguesa Hospital Sao Paulo
Abizaid, Alexandre A.C.
Brazil, Sao Paulo
Universidade de São Paulo
Alfonso, Fernando
Spain, Madrid
Hospital Universitario de la Princesa
Eltchaninoff, Helénè
France, Caen
Normandie Université
Søndergaard, Lars
Denmark, Copenhagen
Rigshospitalet
Latib, Azeem M.
Italy, Milan
Irccs Ospedale San Raffaele
United States, New York
Montefiore Medical Center
Le Breton, Hervé
France, Rennes
Centre Hospitalier Universitaire de Rennes
Servoz, Clément
France, Toulouse
Hôpital Rangueil
Webb, John G.
Canada, Vancouver
St. Paul's Hospital, Vancouver
Sponga, Sandro
Italy, Udine
Policlinico Universitario, Udine
Makkar, Rajendra R.
United States, Los Angeles
Cedars-sinai Medical Center
Kini, Annapoorna S.
United States, New York
The Mount Sinai Hospital
Boukhris, Marouane
Canada, Montreal
Centre Hospitalier de L'universite de Montreal
Holzhey, David Michael
Germany, Leipzig
Herzzentrum Leipzig
Rodés-Cabau, Josep
Canada, Quebec
Université Laval
Spain, Barcelona
Hospital Clinic Barcelona
Statistics
Citations: 17
Authors: 42
Affiliations: 53
Identifiers
Doi:
10.1016/j.jacc.2021.11.056
ISSN:
07351097
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study
Quasi Experimental Study